ଟେଜେପେଲୁମାବ

ଟେଜେପେଲୁମାବ
	Structural basis for inhibition of TSLP-signaling by Tezepelumab (PDB 5J13)
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	thymic stromal lymphopoietin (TSLP)
Clinical data
Trade names	Tezspire
Synonyms	MEDI9929, AMG 157, tezepelumab-ekko
AHFS/Drugs.com	monograph
data	US DailyMed: Tezepelumab;
Routes of; administration	Subcutaneous
Legal status
Legal status	CA: ℞-only / Schedule D; US: ℞-only ; EU: Rx-only ;
Chemical and physical data
Formula	C6400H9844N1732O1992S52
Molar mass	୧,୪୪,୫୯୦.୪0 g·mol−1

ଟେଜେପେଲୁମାବ (ଇଂରାଜୀ ଭାଷାରେ Tezepelumab), ତେଜସ୍ପାୟାର ବେପାର ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ଆଜ୍‌ମା ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୪] ^[୩] ନିର୍ଦ୍ଦିଷ୍ଟ ଭାବରେ ଏହା ଅତି ଭୟଙ୍କର ଆଜମା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ, ଯାହା ଅନ୍ୟ ଔଷଧ ଦ୍ୱାରା ନିୟନ୍ତ୍ରିତ ହୋଇନଥାଏ, ଅତି କମରେ ୧୨ ବର୍ଷ ବୟସର ରୋଗୀ ହୋଇଥିବ ।^[୩] ଏହା ପ୍ରତି ୪ ସପ୍ତାହରେ ଥରେ ଚର୍ମ ତଳେ ଇଞ୍ଜେକସନ ଆକାରରେ ଦିଆଯାଏ ।^[୩]

ସବୁଠାରୁ ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଗଣ୍ଠି ଏବଂ ଗଳା ଯନ୍ତ୍ରଣା ହୁଏ ।^[୩] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଆଲର୍ଜି ପ୍ରତିକ୍ରିୟା ହୋଇପାରେ ।^[୪] ଗର୍ଭାବସ୍ଥାରେ କ୍ଷତିର କୌଣସି ପ୍ରମାଣ ନଥିବାବେଳେ, ଏପରି ବ୍ୟବହାର ଭଲ ଭାବରେ ଅଧ୍ୟୟନ କରାଯାଇ ନାହିଁ ।^[୪] ଏହା ଏକ ମୋନୋକ୍ଲୋନାଲ ଆଣ୍ଟିବଡି ଯାହା ଥିମିକ୍ ଷ୍ଟ୍ରୋମାଲ୍ ଲିମ୍ଫୋପୋଏଟିନ (TSLP) କୁ ଅବରୋଧ କରିଥାଏ, ଫଳସ୍ୱରୂପ ବାୟୁପଥରେ କମ୍ ପ୍ରଦାହ ହୁଏ ।^[୪] ^[୩]

୨୦୨୧ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏବଂ ୨୦୨୨ରେ ୟୁରୋପରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ଟେଜେପେଲୁମାବକୁ ଅନୁମୋଦନ କରାଯାଇଥିଲା ।^[୪] ^[୩] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୨୨ ସୁଦ୍ଧା ବର୍ଷକୁ ଏହା ପିଛା ପ୍ରାୟ ୪୮,୦୦୦ ଡଲାର ଖର୍ଚ୍ଚ ହୋଇଥାଏ ।^[୬] ବ୍ରିଟେନରେ ଏହା ଅନୁମୋଦିତ ହୋଇଥିବାବେଳେ ୨୦୨୨ ସୁଦ୍ଧା ବଜାରରେ ଉପଲବ୍‌ଧ ହୋଇନାହିଁ ।^[୬]

ଆଧାର

↑ Verstraete K, Peelman F, Braun H, Lopez J, Van Rompaey D, Dansercoer A, et al. (April 2017). "Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma". Nature Communications. 8 (1): 14937. Bibcode:2017NatCo...814937V. doi:10.1038/ncomms14937. PMC 5382266. PMID 28368013.
↑ "Tezspire Product information". Health Canada. 25 April 2012. Archived from the original on 1 October 2022. Retrieved 1 October 2022.
↑ ^୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ ^୩.୫ ^୩.୬ "Tezspire EPAR". European Medicines Agency. 19 July 2022. Archived from the original on 22 September 2022. Retrieved 21 September 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ ^୪.୫ "Tezspire- tezepelumab-ekko injection, solution". DailyMed. Archived from the original on 25 December 2021. Retrieved 24 December 2021.
↑ "Tezspire (tezepelumab) approved in the US for severe asthma". AstraZeneca (Press release). 17 December 2021. Archived from the original on 18 December 2021. Retrieved 17 December 2021.
↑ ^୬.୦ ^୬.୧ "Tezepelumab". SPS - Specialist Pharmacy Service. 16 March 2018. Archived from the original on 6 March 2022. Retrieved 24 October 2022.

[:0-1] Verstraete K, Peelman F, Braun H, Lopez J, Van Rompaey D, Dansercoer A, et al. (April 2017). "Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma". Nature Communications. 8 (1): 14937. Bibcode:2017NatCo...814937V. doi:10.1038/ncomms14937. PMC 5382266. PMID 28368013.

[2] "Tezspire Product information". Health Canada. 25 April 2012. Archived from the original on 1 October 2022. Retrieved 1 October 2022.

[EPAR2022-3] ୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ ^୩.୫ ^୩.୬ "Tezspire EPAR". European Medicines Agency. 19 July 2022. Archived from the original on 22 September 2022. Retrieved 21 September 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[PI2022-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ ^୪.୫ "Tezspire- tezepelumab-ekko injection, solution". DailyMed. Archived from the original on 25 December 2021. Retrieved 24 December 2021.

[AstraZeneca_PR_20211217-5] "Tezspire (tezepelumab) approved in the US for severe asthma". AstraZeneca (Press release). 17 December 2021. Archived from the original on 18 December 2021. Retrieved 17 December 2021.

[SPS2022-6] ୬.୦ ^୬.୧ "Tezepelumab". SPS - Specialist Pharmacy Service. 16 March 2018. Archived from the original on 6 March 2022. Retrieved 24 October 2022.

[୪]

[୩]

[୧]

[୨]

[୫]

[୬]